QVQ Holding BV

Webpage: QVQ Holding BV

General description
QVQ Holding BV is a small biotech company that develops camelid-derived single domain antibody fragments (sdAb, VHH or nanobody) as a contract research supplier to universities, medical centres and the industry. QVQ has >15 years of experience in the field of generation, production, purification and conjugation of small camelid-derived antibody-fragments (VHH or nanobodies). In addition, QVQ develops an own pipeline of products for early detection, imaging and therapeutic treatment of cancer, infectious diseases and age-related diseases. QVQ has expertise in bioengineering VHH for the development of analytical and diagnostics tools and applies the llama-antibody technology for generating this pipeline of detection and imaging molecules.

Key research facilities, infrastructures and equipment
On-site facilities that QVQ offers include: phage-display technology (dedicated lab), expression and affinity purification (2x Äkta) of antibodies in bacteria and yeast (5L-fermentor), proprietary C-Direct tag that allows site-directional conjugation and bio-informatics to optimize affinity, production yields and purification. The location of QVQ on the Utrecht Science Park and collaborative partners provide access to many additional research facilities.

Project members

Dr. Ing. Raimond Heukers is CSO at QVQ Holding BV. As such, he is responsible for the technological expertise and progress of the company and for QVQs contribution to national and international research projects on the early detection and treatment of disease. Raimond has a background in chemistry, biochemistry and biomedical sciences. He obtained his PhD in cell biology at Utrecht University and then acquired additional expertise in the development and utilization of antibodies, fragments (like nanobodies), fusion constructs and other scaffolds for the manipulation and therapeutic targeting of tumor-related receptors. As a postdoc, dr. Heukers has established the nanobody selection platform at the VU for the discovery and characterization of GPCR-targeting nanobodies. He has (co-)authored 20+ peer reviewed publications and co-supervised multiple PhD students in various national and international projects, including ONCORNET1.0.

Website: http://www.qvquality.com/corporate/

Dr. Edward Dolk is the (co-)founder and CEO of QVQ. He has 20+ years of experience with llama antibodies and an impressive network in scientific and business communities. Dr. Dolk contributed significantly to multiple scientific publications, a book chapter on selecting VHH under application conditions and 10+ patents.

Follow us on

Hello everyone!
I am Noemi Karsai and I’m the next in our #ESR introduction series. I’m #ESR11 and I’m originally from Hungary, currently doing my PhD at @UoNLifeSci @COMPARE_UoBUoN, UK.

The transatlantic ECI GPCR symposium #ECIGPCR is about to start, we are ready!! Thanks to the organizers for their excellent job gathering almost 500 people across the globe! @cyclic_Andreas @NicoleAPerry1 @BenderSci @DesislavaNeshe1

My project will be focused on the role of #CXCR4/ACKR3/GRK2 -governed networks in cancer cell migration and metastasis.

Hello 🙂
I am here to continue the series in which all #ESRs are presenting themselves. I am Viviana Marolda and I am in my first year of PhD. I am #ESR13, originally from Italy, and currently, I am working as a PhD student in @CBMSO_CSIC_UAM, at Universidad Autonoma de Madrid.

Hey twitter!
I am @DehanComez. I am taking over the Oncornet account for a while to start a series of all #ESRs writing about themselves and their projects. I am #ESR5, originally from Turkey and right now I am working as a PhD student in @COMPARE_UoBUoN , @UniofNottingham , UK.

New review on #gpcr structural dynamics out in COSB. Great teamwork with the @JanaSelent group. Thanks to @Lundbeckfonden and @novonordiskfond https://lnkd.in/eyjrA5V

ONCORNET2.0 is the successor to #ONCORNET. You can see some of the work of ESRs from the first ONCORNET in this special issue of @MolPharmJournal from 2019, with reviews on #CXCR4 and #ACKR3 structure and function: https://molpharm.aspetjournals.org/content/96/6

Hi everyone – we’re on Twitter! ONCORNET2.0 is a #MarieCurie ITN of 16 ESRs across Europe studying #chemokine #GPCRs #CXCR4 and #ACKR3 in cancer. Our projects cover molecular dynamics, medchem, #pharmacology through to translational work. Follow us for updates from our ESRs!

Hi everyone!

Public service announcement: our Marie-Curie ITN @ONCORNET1 is on Twitter! The 16 wonderful #ECRs working on the project will soon be Tweeting about #GPCR #chemokine #ECR life and #pharmacology

Please #RT & consider a follow or follow back! 🙏😀

Load More…

Contact details

Please contact us at:
info@oncornet.eu

ONCORNET Coordinator
VU University Amsterdam
The Netherlands